{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T15:52:45Z","timestamp":1762876365873,"version":"build-2065373602"},"reference-count":32,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,3,10]],"date-time":"2022-03-10T00:00:00Z","timestamp":1646870400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000867","name":"Robert Wood Johnson Foundation","doi-asserted-by":"publisher","award":["NINDSK08 110919-01"],"award-info":[{"award-number":["NINDSK08 110919-01"]}],"id":[{"id":"10.13039\/100000867","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100005351","name":"Neurosurgery Research and Education Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005351","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006108","name":"National Center for Advancing Translational Sciences","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006108","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["World Neurosurgery"],"published-print":{"date-parts":[[2022,6]]},"DOI":"10.1016\/j.wneu.2022.02.125","type":"journal-article","created":{"date-parts":[[2022,3,11]],"date-time":"2022-03-11T11:51:32Z","timestamp":1646999492000},"page":"e235-e245","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["Surgery for Control of Brain Metastases After Previous Checkpoint Inhibitor Immunotherapy"],"prefix":"10.1016","volume":"162","author":[{"given":"Ramin A.","family":"Morshed","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jason E.","family":"Chung","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniel D.","family":"Cummins","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5884-9301","authenticated-orcid":false,"given":"Vivek","family":"Sudhakar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jacob S.","family":"Young","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mariza","family":"Daras","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shawn L.","family":"Hervey-Jumper","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Philip V.","family":"Theodosopoulos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Manish K.","family":"Aghi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.wneu.2022.02.125_bib1","doi-asserted-by":"crossref","first-page":"1480","DOI":"10.1016\/S1470-2045(18)30700-9","article-title":"Nivolumab plus ipilimumab or nivolumab alone versus ipilimumab alone in advanced melanoma (CheckMate 067): 4-year outcomes of a multicentre, randomised, phase 3 trial","volume":"19","author":"Hodi","year":"2018","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.wneu.2022.02.125_bib2","doi-asserted-by":"crossref","first-page":"1853","DOI":"10.1016\/S0140-6736(17)31601-X","article-title":"Pembrolizumab versus ipilimumab for advanced melanoma: final overall survival results of a multicentre, randomised, open-label phase 3 study (KEYNOTE-006)","volume":"390","author":"Schachter","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.wneu.2022.02.125_bib3","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1056\/NEJMoa1709684","article-title":"Overall survival with combined nivolumab and ipilimumab in advanced melanoma","volume":"377","author":"Wolchok","year":"2017","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.wneu.2022.02.125_bib4","doi-asserted-by":"crossref","first-page":"2018","DOI":"10.1056\/NEJMoa1501824","article-title":"Pembrolizumab for the treatment of non-small-cell lung cancer","volume":"372","author":"Garon","year":"2015","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.wneu.2022.02.125_bib5","doi-asserted-by":"crossref","first-page":"1540","DOI":"10.1016\/S0140-6736(15)01281-7","article-title":"Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial","volume":"387","author":"Herbst","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.wneu.2022.02.125_bib6","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1056\/NEJMoa1805453","article-title":"Combined nivolumab and ipilimumab in melanoma metastatic to the brain","volume":"379","author":"Tawbi","year":"2018","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.wneu.2022.02.125_bib7","doi-asserted-by":"crossref","first-page":"E281","DOI":"10.1093\/neuros\/nyaa095","article-title":"Immune checkpoint inhibitors for brain metastases: a primer for neurosurgeons","volume":"87","author":"Aquilanti","year":"2020","journal-title":"Neurosurgery"},{"key":"10.1016\/j.wneu.2022.02.125_bib8","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1016\/S1470-2045(16)30053-5","article-title":"Pembrolizumab for patients with melanoma or non-small-cell lung cancer and untreated brain metastases: early analysis of a non-randomised, open-label, phase 2 trial","volume":"17","author":"Goldberg","year":"2016","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.wneu.2022.02.125_bib9","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1016\/S1470-2045(12)70090-6","article-title":"Ipilimumab in patients with melanoma and brain metastases: an open-label, phase 2 trial","volume":"13","author":"Margolin","year":"2012","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.wneu.2022.02.125_bib10","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1016\/S1470-2045(18)30139-6","article-title":"Combination nivolumab and ipilimumab or nivolumab alone in melanoma brain metastases: a multicentre randomised phase 2 study","volume":"19","author":"Long","year":"2018","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.wneu.2022.02.125_bib11","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1056\/NEJMoa1712126","article-title":"Nivolumab plus ipilimumab versus sunitinib in advanced renal-cell carcinoma","volume":"378","author":"Motzer","year":"2018","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.wneu.2022.02.125_bib12","doi-asserted-by":"crossref","first-page":"2108","DOI":"10.1056\/NEJMoa1809615","article-title":"Atezolizumab and nab-paclitaxel in advanced triple-negative breast cancer","volume":"379","author":"Schmid","year":"2018","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.wneu.2022.02.125_bib13","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1097\/CMR.0b013e32834d3d88","article-title":"Safety and clinical activity of ipilimumab in melanoma patients with brain metastases: retrospective analysis of data from a phase 2 trial","volume":"21","author":"Weber","year":"2011","journal-title":"Melanoma Res"},{"key":"10.1016\/j.wneu.2022.02.125_bib14","doi-asserted-by":"crossref","first-page":"1919","DOI":"10.1056\/NEJMoa1709937","article-title":"Durvalumab after chemoradiotherapy in stage III non-small-cell lung cancer","volume":"377","author":"Antonia","year":"2017","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.wneu.2022.02.125_bib15","doi-asserted-by":"crossref","first-page":"e000333","DOI":"10.1136\/jitc-2019-000333","article-title":"Combined immunotherapy with nivolumab and ipilimumab with and without local therapy in patients with melanoma brain metastasis: a DeCOG\u2217 study in 380 patients","volume":"8","author":"Amaral","year":"2020","journal-title":"J\u00a0Immunother Cancer"},{"key":"10.1016\/j.wneu.2022.02.125_bib16","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1093\/neuonc\/noz049","article-title":"A\u00a0multi-institutional analysis of presentation and outcomes for leptomeningeal disease recurrence after surgical resection and radiosurgery for brain metastases","volume":"21","author":"Prabhu","year":"2019","journal-title":"Neuro Oncol"},{"key":"10.1016\/j.wneu.2022.02.125_bib17","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1093\/neuonc\/now127","article-title":"Updates in the management of brain metastases","volume":"18","author":"Arvold","year":"2016","journal-title":"Neuro Oncol"},{"key":"10.1016\/j.wneu.2022.02.125_bib18","doi-asserted-by":"crossref","first-page":"1040","DOI":"10.1016\/S1470-2045(17)30414-X","article-title":"Post-operative stereotactic radiosurgery versus observation for completely resected brain metastases: a single-centre, randomised, controlled, phase 3 trial","volume":"18","author":"Mahajan","year":"2017","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.wneu.2022.02.125_bib19","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1007\/s11060-021-03698-7","article-title":"Local failure after stereotactic radiosurgery (SRS) for intracranial metastasis: analysis from a cooperative, prospective national registry","volume":"152","author":"Asher","year":"2021","journal-title":"J\u00a0Neurooncol"},{"key":"10.1016\/j.wneu.2022.02.125_bib20","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1001\/jamaoncol.2018.4610","article-title":"Comparison of local control of brain metastases with stereotactic radiosurgery vs surgical resection: a secondary analysis of a randomized clinical trial","volume":"5","author":"Churilla","year":"2019","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.wneu.2022.02.125_bib21","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s11060-018-03020-y","article-title":"Concurrent versus non-concurrent immune checkpoint inhibition with stereotactic radiosurgery for metastatic brain disease: a systematic review and meta-analysis","volume":"141","author":"Lu","year":"2019","journal-title":"J\u00a0Neurooncol"},{"key":"10.1016\/j.wneu.2022.02.125_bib22","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1634\/theoncologist.2018-0306","article-title":"Upfront surgical resection of melanoma brain metastases provides a bridge toward immunotherapy-mediated systemic control","volume":"24","author":"Alvarez-Breckenridge","year":"2019","journal-title":"Oncologist"},{"key":"10.1016\/j.wneu.2022.02.125_bib23","first-page":"605","article-title":"Survival after surgical treatment of brain metastases from lung cancer: a follow-up study of 231 patients treated between 1976 and 1991","volume":"83","author":"Wro\u0144ski","year":"1995","journal-title":"J\u00a0Neurosurg"},{"key":"10.1016\/j.wneu.2022.02.125_bib24","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1007\/s00701-013-1619-y","article-title":"The role of surgical resection in the management of brain metastasis: a 17-yearlongitudinal study","volume":"155","author":"Lee","year":"2013","journal-title":"Acta Neurochir (Wien)"},{"key":"10.1016\/j.wneu.2022.02.125_bib25","doi-asserted-by":"crossref","first-page":"1435","DOI":"10.3390\/cancers13061435","article-title":"The debatable benefit of gross-total resection of brain metastases in a comprehensive treatment setting","volume":"13","author":"J\u00fcnger","year":"2021","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.wneu.2022.02.125_bib26","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.1016\/j.ijrobp.2017.07.045","article-title":"Stereotactic radiosurgery with or without whole-brain radiation therapy for limited brain metastases: a secondary analysis of the North Central Cancer Treatment Group N0574 (Alliance) randomized controlled trial","volume":"99","author":"Churilla","year":"2017","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.wneu.2022.02.125_bib27","first-page":"1175","article-title":"Perioperative complications and neurological outcomes of first and second craniotomies among patients enrolled in the Glioma Outcome Project","volume":"98","author":"Chang","year":"2003","journal-title":"J\u00a0Neurosurg"},{"key":"10.1016\/j.wneu.2022.02.125_bib28","doi-asserted-by":"crossref","first-page":"e607","DOI":"10.1016\/j.wneu.2020.03.021","article-title":"Costs and complications associated with resection of supratentorial tumors with and without the operative microscope in the United States","volume":"138","author":"Zhang","year":"2020","journal-title":"World Neurosurg"},{"key":"10.1016\/j.wneu.2022.02.125_bib29","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1001\/jamaoncol.2018.7204","article-title":"Association of neurosurgical resection with development of pachymeningeal seeding in patients with brain metastases","volume":"5","author":"Cagney","year":"2019","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.wneu.2022.02.125_bib30","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1007\/s10585-020-10019-1","article-title":"Breast brain metastases are associated with increased risk of leptomeningeal disease after stereotactic radiosurgery: a systematic review and meta-analysis","volume":"37","author":"Brown","year":"2020","journal-title":"Clin Exp Metastasis"},{"key":"10.1016\/j.wneu.2022.02.125_bib31","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1016\/j.cell.2018.09.018","article-title":"Evolution of metastases in space and time under immune selection","volume":"175","author":"Angelova","year":"2018","journal-title":"Cell"},{"key":"10.1016\/j.wneu.2022.02.125_bib32","doi-asserted-by":"crossref","first-page":"1565","DOI":"10.1126\/science.1203486","article-title":"Cancer immunoediting: integrating immunity\u2019s roles in cancer suppression and promotion","volume":"331","author":"Schreiber","year":"2011","journal-title":"Science (New York, NY)"}],"container-title":["World Neurosurgery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1878875022002728?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1878875022002728?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T09:12:23Z","timestamp":1761815543000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1878875022002728"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6]]},"references-count":32,"alternative-id":["S1878875022002728"],"URL":"https:\/\/doi.org\/10.1016\/j.wneu.2022.02.125","relation":{},"ISSN":["1878-8750"],"issn-type":[{"type":"print","value":"1878-8750"}],"subject":[],"published":{"date-parts":[[2022,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Surgery for Control of Brain Metastases After Previous Checkpoint Inhibitor Immunotherapy","name":"articletitle","label":"Article Title"},{"value":"World Neurosurgery","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.wneu.2022.02.125","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The Author(s). Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}